Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Sally Weiss

Psychiatry Bangor, ME Medical Doctor

NPI 1083787360 CMS profile 275697

700 Mt Hope Ave, Suite 600, Bangor, ME 04401

Open in the dashboard

General payments

$1,700

133 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Sally Weiss of Bangor, ME is reported in the CMS Open Payments database as having received $1,700 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $657 55
2019 General $1,043 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sally Weiss
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Sally Weiss were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Sally Weiss Psychiatry median Middle half National median
2019 $1,043 $184 $59–$605 $163
2020 $657 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Sunovion Pharmaceuticals Inc. $590 65 payments
  2. Otsuka America Pharmaceutical, Inc. $231 12 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $231 15 payments
  4. Lundbeck LLC $222 13 payments
  5. Allergan Inc. $190 16 payments
  6. Shire North American Group Inc $179 11 payments
  7. AstraZeneca Pharmaceuticals LP $57 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,698 131 payments
  2. Education $2 2 payments
Products named General payments · program years 2019–2020
  1. LATUDA $590 65 payments
  2. REXULTI Psychiatry $231 12 payments
  3. TRINTELLIX Neuroscience $195 12 payments
  4. VRAYLAR $190 16 payments
  5. REXULTI Psychiatry $187 11 payments
  6. VYVANSE $156 10 payments
  7. Trintellix Central Nervous System (CNS) $59 4 payments
  8. FASENRA $57 1 payment
  9. BRINTELLIX $35 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record